| 1 | 1984 | Company Founded - Opthea was originally established as Circadian Technologies Limited. |
|---|
| 2 | 2015 | Company Rebranding - Opthea shifted its focus primarily to developing treatments for retinal diseases such as Wet AMD. |
|---|
| 3 | 2018-2020 | Phase 1/2a Trials (Sozinibercept) - Early clinical trials began to assess safety and efficacy in combination with anti-VEGF therapies. |
|---|
| 4 | 2021-2022 | Phase 2b Trials - Enrolled 366 Wet AMD patients. Top-line data: +5.7 letter improvement in BCVA at 24 weeks. |
|---|
| 5 | September 2023 | Capital Raising - Issued 160 million shares to institutional investors and 16 million shares to retail investors, raising A$82 million. |
|---|
| 6 | December 2023 | Amended DFA with Carlyle/Abingworth - Provided US$170 million in non-equity funding. |
|---|
| 7 | February 2024 | Phase 3 COAST Trial Enrollment Complete - 998 patients enrolled. |
|---|
| 8 | May 2024 | Phase 3 SHORE Trial Enrollment Complete - 986 patients enrolled. |
|---|
| 9 | June 2024 | Capital Raising - Issued shares to raise A$171.5 million, with an additional retail component raising A$55.9 million. |
|---|
| 10 | April 2025 | Top-line Data (COAST Trial) - Expected release of 52-week safety and efficacy results. |
|---|
| 11 | July-August 2025 | Top-line Data (SHORE Trial) - Expected release of 52-week safety and efficacy results. |
|---|
| 12 | September 2025 | OPTOA Options Expiry - OPTOA options (A$0.80 exercise price) expire. |
|---|
| 13 | April 2026 | 12-Month Safety Review (COAST Trial) - Long-term safety review of COAST trial. |
|---|
| 14 | June 2026 | OPTOB Options Expiry - OPTOB options (A$1.00 exercise price) expire. |
|---|
| 15 | July-August 2026 | 12-Month Safety Review (SHORE Trial) - Long-term safety review of SHORE trial. |
|---|
| 16 | Mid to Late 2026 | FDA Approval (Potential) - Sozinibercept could be approved for U.S. market entry. |
|---|
| 17 | Mid to Late 2026 | Capital Raising (for Commercialization) - Expected capital raise to fund commercialization. |
|---|
| 18 | Late 2026 - Early 2027 | Commercialization (Sozinibercept) - Sozinibercept could enter the U.S. market following FDA approval. |
|---|
(20min delay)